LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 4866

Search options

  1. Article ; Online: Equity M&M - Adaptation of the Morbidity and Mortality Conference to Analyze and Confront Structural Inequity in Internal Medicine.

    Ganguly, Anisha P / Oren, Hannah / Jack, Helen E / Abe, Ryan

    Journal of general internal medicine

    2023  Volume 39, Issue 5, Page(s) 867–872

    Abstract: Background: At morbidity and mortality (M&M) conferences, medical teams review cases for medical ... in the M&M format to systematically analyze adverse patient outcomes rooted in social and structural ... and Dallas, TX.: Participants: Equity M&M conferences were held 11 times, each with approximately ...

    Abstract Background: At morbidity and mortality (M&M) conferences, medical teams review cases for medical education and system improvement. Adverse outcomes are often driven by social inequity, but processes to analyze such outcomes are lacking.
    Aim: Adapt quality improvement and patient safety (QIPS) tools in the M&M format to systematically analyze adverse patient outcomes rooted in social and structural determinants of health (SSDH).
    Setting: One-hour conferences conducted in health systems in Seattle, WA, and Dallas, TX.
    Participants: Equity M&M conferences were held 11 times, each with approximately 45 participants comprised of internal medicine trainees, faculty, and non-medical staff.
    Program description: Conferences included a case narrative and counternarrative highlighting SSDH, an equity-framed root cause analysis, and potential interventions.
    Program evaluation: Conferences were received well across both institutions. Following conferences, most respondents reported increased identification of opportunities for action towards equity (88.5%) and confidence in discussing equity issues with colleagues (92.3%).
    Discussion: Equity M&M conferences are a structured tool for deconstructing and confronting structural inequity that leads to adverse patient outcomes. Evaluations demonstrate educational impact on participants. Anecdotal examples suggest institutional impact. Other health systems could adopt this model for similar advocacy and system improvement.
    MeSH term(s) Humans ; Internal Medicine/education ; Congresses as Topic ; Morbidity/trends ; Quality Improvement ; Social Determinants of Health ; Patient Safety ; Health Equity ; Healthcare Disparities
    Language English
    Publishing date 2023-10-30
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 639008-0
    ISSN 1525-1497 ; 0884-8734
    ISSN (online) 1525-1497
    ISSN 0884-8734
    DOI 10.1007/s11606-023-08487-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Book ; Online: Minimum Cut in $O(m\log^2 n)$ Time

    Gawrychowski, Paweł / Mozes, Shay / Weimann, Oren

    2019  

    Abstract: ... vertex graph $G$ with high probability in $O(m \log^2 n)$ time. This is the first improvement to Karger's ... celebrated $O(m \log^3 n)$ time algorithm from 1996. Our main technical contribution is a deterministic $O(m ... We give a randomized algorithm that finds a minimum cut in an undirected weighted $m$-edge $n$ ...

    Abstract We give a randomized algorithm that finds a minimum cut in an undirected weighted $m$-edge $n$-vertex graph $G$ with high probability in $O(m \log^2 n)$ time. This is the first improvement to Karger's celebrated $O(m \log^3 n)$ time algorithm from 1996. Our main technical contribution is a deterministic $O(m \log n)$ time algorithm that, given a spanning tree $T$ of $G$, finds a minimum cut of $G$ that 2-respects (cuts two edges of) $T$.
    Keywords Computer Science - Data Structures and Algorithms
    Publishing date 2019-11-04
    Publishing country us
    Document type Book ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  3. Article ; Online: Expression of a recombinant, 4'-Phosphopantetheinylated, active M. tuberculosis fatty acid synthase I in E. coli.

    Baron, Szilvia / Peleg, Yoav / Grunwald, Jacob / Morgenstern, David / Elad, Nadav / Peretz, Moshe / Albeck, Shira / Levin, Yishai / Welch, John T / DeWeerd, Kim A / Schwarz, Alon / Burstein, Yigal / Diskin, Ron / Shakked, Zippora / Zimhony, Oren

    PloS one

    2018  Volume 13, Issue 9, Page(s) e0204457

    Abstract: Background: Fatty acid synthase 1 (FAS I) from Mycobacterium tuberculosis (Mtb) is an essential protein and a promising drug target. FAS I is a multi-functional, multi-domain protein that is organized as a large (1.9 MDa) homohexameric complex. Acyl ... ...

    Abstract Background: Fatty acid synthase 1 (FAS I) from Mycobacterium tuberculosis (Mtb) is an essential protein and a promising drug target. FAS I is a multi-functional, multi-domain protein that is organized as a large (1.9 MDa) homohexameric complex. Acyl intermediates produced during fatty acid elongation are attached covalently to an acyl carrier protein (ACP) domain. This domain is activated by the transfer of a 4'-Phosphopantetheine (4'-PP, also termed P-pant) group from CoA to ACP catalyzed by a 4'-PP transferase, termed acyl carrier protein synthase (AcpS).
    Methods: In order to obtain an activated FAS I in E. coli, we transformed E. coli with tagged Mtb fas1 and acpS genes encoded by a separate plasmid. We induced the expression of Mtb FAS I following induction of AcpS expression. FAS I was purified by Strep-Tactin affinity chromatography.
    Results: Activation of Mtb FAS I was confirmed by the identification of a bound P-pant group on serine at position 1808 by mass spectrometry. The purified FAS I displayed biochemical activity shown by spectrophotometric analysis of NADPH oxidation and by CoA production, using the Ellman reaction. The purified Mtb FAS I forms a hexameric complex shown by negative staining and cryo-EM.
    Conclusion: Purified hexameric and active Mtb FAS I is required for binding and drug inhibition studies and for structure-function analysis of this enzyme. This relatively simple and short procedure for Mtb FAS I production should facilitate studies of this enzyme.
    MeSH term(s) Antitubercular Agents ; Bacterial Proteins/genetics ; Bacterial Proteins/isolation & purification ; Bacterial Proteins/metabolism ; Bacterial Proteins/ultrastructure ; Drug Discovery ; Escherichia coli/enzymology ; Escherichia coli/genetics ; Fatty Acid Synthases/genetics ; Fatty Acid Synthases/isolation & purification ; Fatty Acid Synthases/metabolism ; Fatty Acid Synthases/ultrastructure ; Genetic Vectors ; Mycobacterium tuberculosis/enzymology ; Mycobacterium tuberculosis/genetics ; Protein Binding ; Recombinant Proteins/genetics ; Recombinant Proteins/isolation & purification ; Recombinant Proteins/metabolism ; Recombinant Proteins/ultrastructure ; Transformation, Bacterial
    Chemical Substances Antitubercular Agents ; Bacterial Proteins ; Recombinant Proteins ; Fatty Acid Synthases (EC 2.3.1.85)
    Language English
    Publishing date 2018-09-24
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 1932-6203
    ISSN (online) 1932-6203
    DOI 10.1371/journal.pone.0204457
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Use of Tc-99 m thyroid scans in borderline congenital hypothyroidism.

    Oren, Asaf / Wang, Michael Ke / Brnjac, Lori / Mahmud, Farid H / Palmert, Mark R

    Clinical endocrinology

    2016  Volume 84, Issue 3, Page(s) 438–444

    Abstract: Background: Mild or borderline congenital hypothyroidism [often referred to as mild neonatal hyperthyrotropinemia (MNH)] is characterized by an abnormal newborn screen (NBS), followed by mildly elevated TSH and normal FT4 on confirmatory testing. This ... ...

    Abstract Background: Mild or borderline congenital hypothyroidism [often referred to as mild neonatal hyperthyrotropinemia (MNH)] is characterized by an abnormal newborn screen (NBS), followed by mildly elevated TSH and normal FT4 on confirmatory testing. This condition is increasingly observed, but data regarding optimal management are limited.
    Objective: Examine the use of routine technetium thyroid scanning (TS) in the management of MNH.
    Methods: Retrospective study of infants with MNH between 2000 and 2011. We assessed the clinical course of infants with MNH according to TS results; as a comparator, infants with classic congenital hypothyroidism (CH) were analysed in parallel.
    Results: We identified 69 infants (52% boys) with MNH and 164 (34% boys) with classic CH. TS results were divided into four subgroups: no uptake in 7% of MNH vs 24% of classic CH (P < 0·01), decreased uptake/anatomical abnormalities in 39% vs 46% (p = NS), increased uptake in 35% vs 26% (p = NS) and normal uptake in 19% vs 4% (P < 0·01). In MNH, neither NBS-TSH, confirmatory TSH and FT4, mean LT-4 treatment doses and number of dose escalations, nor post-treatment FT4 and TSH differed among the four subgroups. In contrast, clinical features in infants with classic CH differed among the subgroups. Among MNH infants who reached 3 years of age, trial-off treatment was successful in 6 of 11 (55%) with no apparent difference in success rates among TS subgroups.
    Conclusions: The information provided by TS during evaluation of MNH does not predict clinical course; obtaining these scans in infants with MNH may not be an effective use of healthcare resources.
    MeSH term(s) Congenital Hypothyroidism/diagnosis ; Congenital Hypothyroidism/drug therapy ; Female ; Humans ; Infant, Newborn ; Male ; Neonatal Screening/methods ; Retrospective Studies ; Technetium ; Thyrotropin/metabolism ; Thyroxine/therapeutic use
    Chemical Substances Technetium (7440-26-8) ; Thyrotropin (9002-71-5) ; Thyroxine (Q51BO43MG4)
    Language English
    Publishing date 2016-03
    Publishing country England
    Document type Journal Article
    ZDB-ID 121745-8
    ISSN 1365-2265 ; 0300-0664
    ISSN (online) 1365-2265
    ISSN 0300-0664
    DOI 10.1111/cen.12807
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Analogs of the antituberculous agent pyrazinamide are competitive inhibitors of NADPH binding to M. tuberculosis fatty acid synthase I.

    Sayahi, Halimah / Pugliese, Kaitlin M / Zimhony, Oren / Jacobs, William R / Shekhtman, Alexander / Welch, John T

    Chemistry & biodiversity

    2012  Volume 9, Issue 11, Page(s) 2582–2596

    Abstract: Analogs of pyrazinamide (=pyrazine-2-carboxamide; PZA), an essential component of short-course antituberculous chemotherapy, such as 5-chloropyrazinamide (5-Cl-PZA) act as competitive inhibitors of NADPH binding to purified mycobacterial fatty acid ... ...

    Abstract Analogs of pyrazinamide (=pyrazine-2-carboxamide; PZA), an essential component of short-course antituberculous chemotherapy, such as 5-chloropyrazinamide (5-Cl-PZA) act as competitive inhibitors of NADPH binding to purified mycobacterial fatty acid synthase I (FAS I) as shown by Saturation Transfer Difference (STD) NMR studies. In addition, pyrazinoic acid esters (POE) and 5-Cl-POE reversibly bind to FAS I with the relatively greater affinity of longer-chain esters for FAS I, clear from the STD amplification factors. The competitive binding of PZA and 5-Cl-PZA clearly illustrates that both agents bind FAS. In contrast to PZA, at low NADPH concentrations 5-Cl-PZA is a cooperative inhibitor of NADPH binding.
    MeSH term(s) Antitubercular Agents/chemistry ; Antitubercular Agents/pharmacology ; Bacterial Proteins/antagonists & inhibitors ; Bacterial Proteins/metabolism ; Fatty Acid Synthases/antagonists & inhibitors ; Fatty Acid Synthases/metabolism ; Humans ; Mycobacterium tuberculosis/drug effects ; Mycobacterium tuberculosis/enzymology ; NADP/metabolism ; Protein Binding/drug effects ; Pyrazinamide/analogs & derivatives ; Pyrazinamide/pharmacology ; Tuberculosis/drug therapy ; Tuberculosis/microbiology
    Chemical Substances Antitubercular Agents ; Bacterial Proteins ; Pyrazinamide (2KNI5N06TI) ; NADP (53-59-8) ; Fatty Acid Synthases (EC 2.3.1.85) ; fatty acid synthase I, mycobacteria (EC 6.4.-)
    Language English
    Publishing date 2012-11
    Publishing country Switzerland
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S.
    ZDB-ID 2139001-0
    ISSN 1612-1880 ; 1612-1872
    ISSN (online) 1612-1880
    ISSN 1612-1872
    DOI 10.1002/cbdv.201200291
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Expression of a recombinant, 4'-Phosphopantetheinylated, active M. tuberculosis fatty acid synthase I in E. coli.

    Szilvia Baron / Yoav Peleg / Jacob Grunwald / David Morgenstern / Nadav Elad / Moshe Peretz / Shira Albeck / Yishai Levin / John T Welch / Kim A DeWeerd / Alon Schwarz / Yigal Burstein / Ron Diskin / Zippora Shakked / Oren Zimhony

    PLoS ONE, Vol 13, Iss 9, p e

    2018  Volume 0204457

    Abstract: BACKGROUND:Fatty acid synthase 1 (FAS I) from Mycobacterium tuberculosis (Mtb) is an essential protein and a promising drug target. FAS I is a multi-functional, multi-domain protein that is organized as a large (1.9 MDa) homohexameric complex. Acyl ... ...

    Abstract BACKGROUND:Fatty acid synthase 1 (FAS I) from Mycobacterium tuberculosis (Mtb) is an essential protein and a promising drug target. FAS I is a multi-functional, multi-domain protein that is organized as a large (1.9 MDa) homohexameric complex. Acyl intermediates produced during fatty acid elongation are attached covalently to an acyl carrier protein (ACP) domain. This domain is activated by the transfer of a 4'-Phosphopantetheine (4'-PP, also termed P-pant) group from CoA to ACP catalyzed by a 4'-PP transferase, termed acyl carrier protein synthase (AcpS). METHODS:In order to obtain an activated FAS I in E. coli, we transformed E. coli with tagged Mtb fas1 and acpS genes encoded by a separate plasmid. We induced the expression of Mtb FAS I following induction of AcpS expression. FAS I was purified by Strep-Tactin affinity chromatography. RESULTS:Activation of Mtb FAS I was confirmed by the identification of a bound P-pant group on serine at position 1808 by mass spectrometry. The purified FAS I displayed biochemical activity shown by spectrophotometric analysis of NADPH oxidation and by CoA production, using the Ellman reaction. The purified Mtb FAS I forms a hexameric complex shown by negative staining and cryo-EM. CONCLUSION:Purified hexameric and active Mtb FAS I is required for binding and drug inhibition studies and for structure-function analysis of this enzyme. This relatively simple and short procedure for Mtb FAS I production should facilitate studies of this enzyme.
    Keywords Medicine ; R ; Science ; Q
    Subject code 572
    Language English
    Publishing date 2018-01-01T00:00:00Z
    Publisher Public Library of Science (PLoS)
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  7. Article: Schnitzler syndrome: chronic urticaria, fever and immunoglobulin M monoclonal gammopathy.

    Shibolet, Oren / Schatz, Olga / Krieger, Michal / Maly, Alexander / Caraco, Yoseph

    The Israel Medical Association journal : IMAJ

    2002  Volume 4, Issue 6, Page(s) 466–467

    MeSH term(s) Anti-Inflammatory Agents/therapeutic use ; Anti-Inflammatory Agents, Non-Steroidal/therapeutic use ; Aspirin/therapeutic use ; Diagnosis, Differential ; Humans ; Male ; Middle Aged ; Prednisone/therapeutic use ; Schnitzler Syndrome/diagnosis ; Schnitzler Syndrome/drug therapy ; Schnitzler Syndrome/pathology
    Chemical Substances Anti-Inflammatory Agents ; Anti-Inflammatory Agents, Non-Steroidal ; Aspirin (R16CO5Y76E) ; Prednisone (VB0R961HZT)
    Language English
    Publishing date 2002-06
    Publishing country Israel
    Document type Case Reports ; Journal Article
    ZDB-ID 2008291-5
    ISSN 1565-1088 ; 0021-2180
    ISSN 1565-1088 ; 0021-2180
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Comments on: "A polyphasic approach leading to the revision of the genus Planktothrix (Cyanobacteria) and its type species, P. agardhii, and proposal for integrating the emended valid botanical taxa, as well as three new species, Planktothrix paucivesiculata sp. nov.(ICNP), Planktothrix tepida sp. nov.(ICNP), and Planktothrix serta sp. nov.(ICNP), as genus and species names with nomenclature standing under the ICNP," by V. Gaget, M. Welker, R. Rippka, and N. Tandeau de Marsac, Syst. Appl. Microbiol. (2015), http://dx.doi.org/10.1016/j.syapm.2015.02.004.

    Oren, Aharon

    Systematic and applied microbiology

    2015  Volume 38, Issue 3, Page(s) 159–160

    MeSH term(s) Cyanobacteria/classification ; Cyanobacteria/genetics
    Language English
    Publishing date 2015-05
    Publishing country Germany
    Document type Comment ; Journal Article
    ZDB-ID 283612-9
    ISSN 1618-0984 ; 0723-2020
    ISSN (online) 1618-0984
    ISSN 0723-2020
    DOI 10.1016/j.syapm.2015.03.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: [Rezension von: Levin-Waldman, Oren M., The case of the minimum wage]

    Couch, Kenneth A / Levin-Waldman, Oren M

    ILR review : the journal of work and policy Vol. 56, No. 1 (2002/03), p. 180-181

    2002  Volume 56, Issue 1, Page(s) 180–181

    Author's details Kenneth A. Couch
    Keywords 40#49
    Language English
    Publisher Sage Publications
    Publishing place Thousand Oaks, Calif
    Document type Article
    ZDB-ID 218617-2 ; 2066463-1
    ISSN 2162-271X ; 0019-7939
    ISSN (online) 2162-271X
    ISSN 0019-7939
    Database ECONomics Information System

    More links

    Kategorien

  10. Article: Increased inflammation in lysozyme M-deficient mice in response to Micrococcus luteus and its peptidoglycan.

    Ganz, Tomas / Gabayan, Victoria / Liao, Hsiang-I / Liu, Lide / Oren, Ami / Graf, Thomas / Cole, Alexander M

    Blood

    2002  Volume 101, Issue 6, Page(s) 2388–2392

    Abstract: ... deficient in lysozyme M after challenge by the normally nonpathogenic and highly lysozyme-sensitive ... lysozyme M-deficient mice developed much more severe lesions than wild-type mice. The tissue injury was due ... to the failure of lysozyme M-deficient mice to inactivate peptidoglycan, resulting in an intense and prolonged ...

    Abstract More than 70 years ago, Alexander Fleming discovered lysozyme and proposed that nonpathogenic bacteria fail to cause disease because they are very susceptible to destruction by lysozyme, an enzyme that is one of the principal proteins of phagocytes. Although much has been learned about the effects of lysozyme in vitro, its biological role in vivo has not been determined. We examined transgenic mice deficient in lysozyme M after challenge by the normally nonpathogenic and highly lysozyme-sensitive bacterium Micrococcus luteus. Despite partial compensation by newly expressed lysozyme P in macrophages, lysozyme M-deficient mice developed much more severe lesions than wild-type mice. The tissue injury was due to the failure of lysozyme M-deficient mice to inactivate peptidoglycan, resulting in an intense and prolonged inflammatory response. Our data indicate that tissue injury is normally limited by prompt degradation of bacterial macromolecules that trigger innate immunity and inflammation.
    MeSH term(s) Animals ; Bacterial Infections/enzymology ; Disease Susceptibility/enzymology ; Gene Expression ; Green Fluorescent Proteins ; Inflammation/enzymology ; Luminescent Proteins/genetics ; Macrophages/enzymology ; Mice ; Mice, Inbred C57BL ; Mice, Transgenic ; Micrococcus luteus/pathogenicity ; Muramidase/analysis ; Muramidase/deficiency ; Muramidase/genetics ; Muramidase/physiology ; Neutrophils/enzymology ; Peptidoglycan ; Recombinant Fusion Proteins
    Chemical Substances Luminescent Proteins ; Peptidoglycan ; Recombinant Fusion Proteins ; Green Fluorescent Proteins (147336-22-9) ; Muramidase (EC 3.2.1.17) ; lysozyme M, mouse (EC 3.2.1.17) ; lysozyme P, mouse (EC 3.2.1.17)
    Language English
    Publishing date 2002-10-31
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, P.H.S.
    ZDB-ID 80069-7
    ISSN 1528-0020 ; 0006-4971
    ISSN (online) 1528-0020
    ISSN 0006-4971
    DOI 10.1182/blood-2002-07-2319
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top